Cyclooxygenase 1 [COX1] expression in type 2 diabetes mellitus: a preliminary study from north India
Egyptian Journal of Medical Human Genetics [The]. 2016; 17 (1): 41-45
in En
| IMEMR
| ID: emr-176212
Responsible library:
EMRO
ABSTRACT
Background and purpose:
The 6th edition of International Diabetes Federation, 2014 shows an estimate of 387 million people with Type 2 diabetes mellitus [T2DM] worldwide, expected to rise to 592 million by 2035. T2DM is a metabolic disorder, one of the reasons being oxidative stress due to impairment in antioxidant enzymes. It leads to several complications such as micro and macrovascular diseases. Cyclooxygenase1 [COX1] enzyme is the rate limiting factor for the arachidonic pathway leading to vascular wall contraction with angiotensin II occurring in heart diseases resulting from T2DM. COX1 determines 6-Keto Prostaglandin F1alpha [6-k-PGF1alpha] level, plays a major role in vasodilation and restricts macrophage platelet aggregation. The aim of the present study was to compare the COX1 expression and level of reactive oxygen species [ROS] in T2DM patients and controls at different time periods in human macrophages in order to find a biomarker or drug target
Search on Google
Index:
IMEMR
Main subject:
Gene Expression
/
Reactive Oxygen Species
/
Cyclooxygenase 1
/
Real-Time Polymerase Chain Reaction
Limits:
Humans
Language:
En
Journal:
Egypt. J. Med. Hum. Genet.
Year:
2016